Special Focus Session
SF 1a - Dose management systems (DMS) and beyond
Lectures
1
Chairperson's introduction
05:00Ioannis Seimenis, Athens / GR
2
Acquisition and effective use of a DMS: the radiologist's perspective
20:00Peter Mildenberger, Mainz / DE
3
Comparison between different dose management tools and their extended capabilities
20:00Hilde Bosmans, Leuven / BE
4
Organ dose estimation using DMS: can we trust it?
15:00Natalia Saltybaeva, Baar / CH
5
Challenges regarding the management of cumulative effective dose
15:00Osvaldo Rampado, Turin / IT
6
Panel discussion: Should/could DMS impact patient dose regulations?
15:00Panel discussion: Should/could DMS impact patient dose regulations?
5 min
Chairperson's introduction
Ioannis Seimenis, Athens / Greece
20 min
Acquisition and effective use of a DMS: the radiologist's perspective
Peter Mildenberger, Mainz / Germany
- To understand the value of DMS integration into clinical information systems.
- To appreciate the effective benefits of DMS for patient dose optimisation.
- To learn about the potential development of next-generation DMS.
20 min
Comparison between different dose management tools and their extended capabilities
Hilde Bosmans, Leuven / Belgium
- To learn about different approaches in data archiving and processing with DMS.
- To appreciate optimal strategies for extracting relevant information and diagnostic reference levels.
- To understand extended DMS capabilities, such as image quality evaluation.
15 min
Organ dose estimation using DMS: can we trust it?
Natalia Saltybaeva, Baar / Switzerland
- To understand the benefits and limitations of DMS for organ dose assessment.
- To learn which methods can be used to validate organ dose values calculated by DMS.
- To comprehend uncertainties for organ dose estimations using DMS and identify factors influencing these uncertainties.
15 min
Challenges regarding the management of cumulative effective dose
Osvaldo Rampado, Turin / Italy
- To understand how DMS employment can assist in identifying patients with high cumulative doses.
- To evaluate which procedures and clinical pathways involve high cumulative risks.
- To learn how cumulative dose data can be used for optimisation actions.
15 min
Panel discussion: Should/could DMS impact patient dose regulations?
Ioannis Seimenis
Athens / Greece
Ioannis Seimenis
Athens / GreecePeter Mildenberger
Mainz / GermanyHilde Bosmans
Leuven / BelgiumNatalia Saltybaeva
Baar / SwitzerlandOsvaldo Rampado
Turin / Italy